PHARMACEUTICALS TREATING BRAIN CONDITIONS

Brand Owner Address Description
AMYLON Amylon Therapeutics BV Zernikedreef 9 NL-2333 CK Leiden Netherlands Pharmaceuticals for treating brain conditions; pharmaceutical compositions for treating brain conditions; pharmaceutical drugs for treating brain conditions; chemico-pharmaceutical preparations for treating brain conditions; sanitary preparations for medical purposes;Business fundraising for others; financial investment information; financial investment research; capital investment; venture capital funding services for inventors; venture capital funding services to emerging and start-up companies;The wording AMYLON has no meaning in a foreign language.;Laboratory research services relating to pharmaceuticals; medical research; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development in the field of biotechnology; biological research; clinical research in the field of biology and brain conditions; biomedical research services; pharmaceutical research services; research of pharmaceuticals; pharmaceutical products development; testing of pharmaceuticals; pharmaceutical drug development services; research and development of new products for the pharmaceutical industry; consultancy relating to pharmaceutical research and development; consultancy in the field of pharmaceutical research; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention relates to methods and compositions for treating selected conditions of the central and peripheral nervous systems employing non-synaptic mechanisms. More specifically, one aspect of the present invention relates to methods and materials for treating seizure and seizure disorders, epilepsy, status epilepticus, migraine, spreading depression, intracranial hypertension; for treating the pathophysiological effects of head trauma, stroke, ischemia and hypoxia; for treating or protecting from the pathophysiological effects of neurotoxic agents such as ethanol; and for treating neurophsyciatric disorders and central nervous system edema by administering agents that modulate ionic concentrations and/or ionic gradients in the brain, particularly ion-dependent or cation-chloride cotransporter antagonists. Electrolyte cotransport antagonists and combinations of such compositions with other agents for treating various conditions are disclosed. The present invention also relates to methods and compositions for treating pain by administering ion-dependent cotransporter antagonists. Methods and compositions for enhancing cortical function, for example, in centers of cognition, learning and memory, by administering ion-dependent cotransporter agonists are disclosed.